I believe that ProQR Therapeutics (PRQR) is poised for significant growth following the recent appointment of Dr. Peter A. Beal as Chief ADAR Scientist and the successful $75 million public offering. With ongoing advancements in their Axiomer RNA editing platform, now is an opportune time to invest.

Given ProQR Therapeutics' successful $63 million public offering and key collaborations focusing on its Axiomer™ RNA editing technology, I believe the stock is poised for significant growth. The recent uptick in investor interest reinforces my decision to purchase PRQR as it shows strong potential within the RNA therapy sector.